Sign in
Explore the registryTrack Durvalumab +tremelimumab's trials

NEPTUNE

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Durvalumab +TremelimumabOngoingActive not recruitingPhase 3Open NCT02542293 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…